Barbara G Fox

Array ( [id] => 11641056 [patent_doc_number] => 09662405 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-30 [patent_title] => 'Method of treating cancer by administering chimeric antigen receptor comprising anti-GCC antibody' [patent_app_type] => utility [patent_app_number] => 14/879936 [patent_app_country] => US [patent_app_date] => 2015-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29792 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14879936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10761952 [patent_doc_number] => 20160108105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'HUMAN IGG4 FC POLYPEPTIDE VARIANT' [patent_app_type] => utility [patent_app_number] => 14/875746 [patent_app_country] => US [patent_app_date] => 2015-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 10544 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14875746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14665083 [patent_doc_number] => 10370432 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Heterologous targeting peptide grafted AAVS [patent_app_type] => utility [patent_app_number] => 15/516582 [patent_app_country] => US [patent_app_date] => 2015-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 32 [patent_no_of_words] => 22923 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15516582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663654 [patent_doc_number] => 20160009798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'Human Oncostatin M Antibodies and Methods of Use' [patent_app_type] => utility [patent_app_number] => 14/870774 [patent_app_country] => US [patent_app_date] => 2015-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 22106 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14870774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10656210 [patent_doc_number] => 20160002354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'ANTIBODIES TO BONE MARROW STROMAL ANTIGEN 1' [patent_app_type] => utility [patent_app_number] => 14/862850 [patent_app_country] => US [patent_app_date] => 2015-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 48779 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14862850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977562 [patent_doc_number] => 20170281716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 15/512139 [patent_app_country] => US [patent_app_date] => 2015-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 19268 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15512139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10656196 [patent_doc_number] => 20160002340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR MONOCLONAL ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/856588 [patent_app_country] => US [patent_app_date] => 2015-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 85933 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14856588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11304833 [patent_doc_number] => 09512219 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-06 [patent_title] => 'IL-31 monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 14/842903 [patent_app_country] => US [patent_app_date] => 2015-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46767 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14842903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813762 [patent_doc_number] => 20160159923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'ANTIBODIES TO MATRIX METALLOPROTEINASE 9' [patent_app_type] => utility [patent_app_number] => 14/839503 [patent_app_country] => US [patent_app_date] => 2015-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10058 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14839503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12178681 [patent_doc_number] => 20180037617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/505600 [patent_app_country] => US [patent_app_date] => 2015-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 38688 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15505600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866210 [patent_doc_number] => 20170233495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'ANTIBODIES SPECIFIC FOR MMP9' [patent_app_type] => utility [patent_app_number] => 15/503447 [patent_app_country] => US [patent_app_date] => 2015-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 37311 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15503447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026441 [patent_doc_number] => 10035836 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-07-31 [patent_title] => Modified IL-2 variants that selectively activate regulatory T cells [patent_app_type] => utility [patent_app_number] => 15/327813 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 9710 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15327813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700561 [patent_doc_number] => 20160046707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'NEUTRALIZING ANTI-CCL20 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/816989 [patent_app_country] => US [patent_app_date] => 2015-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 38629 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14816989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11297841 [patent_doc_number] => 09505837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-29 [patent_title] => 'Anti-IL-23 antibodies' [patent_app_type] => utility [patent_app_number] => 14/812375 [patent_app_country] => US [patent_app_date] => 2015-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 33817 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14812375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430227 [patent_doc_number] => 20150315239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/805424 [patent_app_country] => US [patent_app_date] => 2015-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 18482 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14805424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757289 [patent_doc_number] => 20170204156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN' [patent_app_type] => utility [patent_app_number] => 15/326936 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 13079 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15326936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678021 [patent_doc_number] => 20160024167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'METHODS AND COMPOSITIONS BASED ON DIPHTHERIA TOXIN-INTERLEUKIN-3 CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/802398 [patent_app_country] => US [patent_app_date] => 2015-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 50574 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14802398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10663640 [patent_doc_number] => 20160009783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'OLIGOMERS FOR TNF SUPERFAMILY INHIBITION, METHODS OF MAKING AND USING' [patent_app_type] => utility [patent_app_number] => 14/796827 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 24052 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10679560 [patent_doc_number] => 20160025705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'PROCESS FOR ASSESSING RISK OF SUBSTANCE ADMINISTRATION' [patent_app_type] => utility [patent_app_number] => 14/796091 [patent_app_country] => US [patent_app_date] => 2015-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5813 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14796091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729329 [patent_doc_number] => 20170190772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'TREATMENT OF LYSOSOMAL DISORDERS (IL-1 ANTAGONISTS)' [patent_app_type] => utility [patent_app_number] => 15/325368 [patent_app_country] => US [patent_app_date] => 2015-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14767 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15325368 [rel_patent_id] =>[rel_patent_doc_number] =>)